First-pass whole-body Magnetic Resonance Angiography (MRA) using the blood-pool contrast medium gadofosveset trisodium: Comparison to gadopentetate dimeglumine

Investigative Radiology

Volumn 42, Issue 9, 2007, Pages 659-664

  Klessen, Christian ^a   Hein, Patrick A ^a   Huppertz, Alexander ^a   Voth, Matthias ^b   Wagner, Moritz ^a   Elgeti, Thomas ^a   Kroll, Hannes ^a   Hamm, Bernd ^a   Taupitz, Matthias ^a   Asbach, Patrick ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Blood pool contrast media; Clinical studies; Contrast media; Magnetic resonance angiography; Magnetic resonance imaging

Indexed keywords

GADOFOSVESET; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FIRST PASS EFFECT; HUMAN; IMAGE QUALITY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; PRIORITY JOURNAL; WHOLE BODY IMAGING;

EID: 34547879246     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318063c635     Document Type: Article

References (25)

1. Borisch I, Horn M, Butz B, et al. Preoperative evaluation of carotid artery stenosis: comparison of contrast-enhanced MR angiography and duplex sonography with digital subtraction angiography. AJNR Am J Neuroradiol. 2003;24:1117-1122.
2. Randoux B, Marro B, Koskas F, et al. Proximal great vessels of aortic arch: comparison of three-dimensional gadolinium-enhanced MR angiography and digital subtraction angiography. Radiology. 2003;229:697-702.
3. De Cobelli F, Venturini M, Vanzulli A, et al. Renal arterial stenosis: prospective comparison of color Doppler US and breath-hold, three-dimensional, dynamic, gadolinium-enhanced MR angiography. Radiology. 2000;214:373-380.
4. Aschenbach R, Eger C, Basche S, et al. Grading of carotid artery stenosis using high resolution dynamic magnetic resonance angiography in comparison to intraarterial digital subtraction angiography. Are stenoses over 70% reliably detectable? Rofo. 2004;176:357-362.
5. Mohrs OK, Oberholzer K, Krummenauer F, et al. Comparison of contrast-enhanced MR angiography of the aortoiliac vessels using a 1.0 molar contrast agent at 1.0 T with intra-arterial digital subtraction angiography. Rofo. 2004;176:985-991.
6. Dormandy J, Heeck L, Vig S. Lower-extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease. Semin Vasc Surg. 1999;12:118-122.
7. von Kemp K, van den Brande P, Peterson T, et al. Screening for concomitant diseases in peripheral vascular patients. Results of a systematic approach. Int Angiol. 1997;16:114-122.
8. Goyen M, Quick HH, Debatin JF, et al. Whole-body three-dimensional MR angiography with a rolling table platform: initial clinical experience. Radiology. 2002;224:270-277.
9. Leiner T, de Vries M, Hoogeveen R, et al. Contrast-enhanced peripheral MR angiography at 3.0 Tesla: initial experience with a whole-body scanner in healthy volunteers. J Magn Reson Imaging. 2003;17:609-614.
10. Kruger DG, Riederer SJ, Grimm RC, et al. Continuously moving table data acquisition method for long FOV contrast-enhanced MRA and whole-body MRI. Magn Reson Med. 2002;47:224-231.
11. Ruehm SG, Goyen M, Barkhausen J, et al. Rapid magnetic resonance angiography for detection of atherosclerosis. Lancet. 2001;357:1086-1091.
12. Hartmann M, Wiethoff AJ, Hentrich HR, et al. Initial imaging recommendations for Vasovist angiography. Eur Radiol. 2006;16(Suppl 2):B15-B23.
13. Rapp JH, Wolff SD, Quinn SF, et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography-multicenter comparative phase III study. Radiology. 2005;236:71-78.
14. Perreault P, Edelman MA, Baum RA, et al. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial. Radiology. 2003;229:811-820.
15. Grist TM, Korosec FR, Peters DC, et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology. 1998;207:539-544.
16. Goyen M, Edelman M, Perreault P, et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology. 2005;236:825-833.
17. Bluemke DA, Stillman AE, Bis KG, et al. Carotid MR angiography: phase II study of safety and efficacy for MS-325. Radiology. 2001;219:114-122.
18. Shamsi K, Yucel EK, Chamberlin P. A Summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: phase II and phase III clinical trials data. Invest Radiol. 2006;41:822-830.
19. Steger-Hartmann T, Graham PB, Muller S, et al. Preclinical safety assessment of Vasovist (Gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography. Invest Radiol. 2006;41:449-459.
20. Nikolaou K, Kramer H, Grosse C, et al. High-spatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. Radiology. 2006;241:861-872.
21. Maki JH, Prince MR, Londy FJ, et al. The effects of time varying intravascular signal intensity and k-space acquisition order on three-dimensional MR angiography image quality. J Magn Reson Imaging. 1996;6:642-651.
22. Weiger M, Pruessmann KP, Kassner A, et al. Contrast-enhanced 3D MRA using SENSE. J Magn Reson Imaging. 2000;12:671-677.
23. Kim JK, Farb RI, Wright GA. Test bolus examination in the carotid artery at dynamic gadolinium-enhanced MR angiography. Radiology. 1998;206:283-289.
24. Heverhagen JT, Funck RC, Schwarz U, et al. Kinetic evaluation of an iv bolus of MR contrast media. Magn Reson Imaging. 2001;19:1025-1030.
25. Goyen M, Herborn CU, Lauenstein TC, et al. Optimization of contrast dosage for gadobenate dimeglumine-enhanced high-resolution whole-body 3D magnetic resonance angiography. Invest Radiol. 2002;37:263-268.